Metagenomi, Inc. Common Stock Asset Resilience Ratio
Metagenomi, Inc. Common Stock asset resilience ratio. Metagenomi, Inc. Common Stock (MGX) has an Asset Resilience Ratio of 47.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Metagenomi, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Metagenomi, Inc. Common Stock (2021–2025)
Asset resilience ratio of Metagenomi, Inc. Common Stock from 2021 to 2025. This chart shows how Metagenomi, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Metagenomi, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Metagenomi, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Metagenomi, Inc. Common Stock (MGX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $81.64 Million | 47.0% |
| Total Liquid Assets | $81.64 Million | 47.00% |
Asset Resilience Insights
- Very High Liquidity: Metagenomi, Inc. Common Stock maintains exceptional liquid asset reserves at 47.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Metagenomi, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Metagenomi, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Metagenomi, Inc. Common Stock Asset Resilience Ratio by Year (2021–2025)
Metagenomi, Inc. Common Stock asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Metagenomi, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 53.86% | $119.08 Million | $221.10 Million | -14.20pp |
| 2024-09-30 | 68.06% | $220.92 Million | $324.60 Million | +32.27pp |
| 2023-09-30 | 35.79% | $130.58 Million | $364.84 Million | -7.08pp |
| 2022-09-30 | 42.87% | $177.69 Million | $414.49 Million | -5.62pp |
| 2021-09-30 | 48.49% | $68.86 Million | $141.99 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more